Department of Internal Medicine, University of Uyo Teaching Hospital, Uyo, Nigeria.
West Afr J Med. 2022 Jul 31;39(7):769-771.
The association of kidney disease and COVID-19 vaccination has been reported with minimal change disease being a common presentation.
Index patient is a 54-year-old female who presented with a history of reduction in urine output within 3 weeks of receiving the Oxford-AztraZeneca COVID-19 vaccine. Her serum creatinine on admission was 1,057 µmol/L with a premorbid serum creatinine of 78 µmol/L. Her vital signs were stable. She was on antihypertensive and antidiabetic medications for hypertension and diabetes mellitus, respectively. Renal biopsy was precluded by her morbid obesity and she was commenced on oral prednisolone. She had 5 sessions of hemodialysis and her serum creatinine gradually reduced to 106 µmol/L, and she is being followed up on an outpatient basis.
We report a case of a female patient with acute kidney injury following COVID-19 Oxford-AztraZeneca vaccination. Further studies are required to better understand the pathogenesis of the renal affectation post-vaccination.
有报道称，肾脏疾病与 COVID-19 疫苗接种之间存在关联，微小病变病是常见的表现。
本例患者为 54 岁女性，在接种牛津-阿斯利康 COVID-19 疫苗后 3 周内出现尿量减少。入院时她的血清肌酐为 1057μmol/L，基础血清肌酐为 78μmol/L。她的生命体征稳定。她因高血压和糖尿病分别服用抗高血压药和降糖药。由于她患有病态肥胖，因此未能进行肾脏活检，遂开始口服泼尼松龙治疗。她接受了 5 次血液透析，血清肌酐逐渐降至 106μmol/L，目前正在门诊接受随访。
我们报告了一例女性患者在接种 COVID-19 牛津-阿斯利康疫苗后发生急性肾损伤。需要进一步的研究来更好地了解疫苗接种后肾脏影响的发病机制。
